New antifungal therapy for fungal meningitis

Researchers from the University of Minnesota Medical School have successfully tested a new antifungal therapy for fungal meningitis. The trial, published in Clinical Infectious Diseases, focused on a new oral formulation of the antifungal medication amphotericin, which can be taken orally and is non-toxic. This is a significant development as conventional amphotericin B can only be administered intravenously and is highly toxic. The trial results showed promising results for the treatment of cryptococcal meningitis, the most common cause of central nervous system infection in people living with HIV. Further clinical trials are needed, but this marks an important step in the treatment of fungal infections.

To top